InsiderClue
← All stocks

BridgeBio Oncology Therapeutics, Inc.

BBOT Net buying
CIK 0001869105 #2802 in the set updated 21 Sep 2026
Bought (120 mo)
$24.00M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$24.00M
+$24.00M against sales at will

By person

11 insiders · 3 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Chen Bihua
Director
$24.00M (3)
—
+$24.00M
6,986,821
$69.87M
—
BridgeBio Pharma LLC entity
10% owner
—
—
—
14,589,846
$145.90M
+5.7%
Helix Holdings II LLC entity
Director
—
—
—
509,000
$5.09M
—
Ben Yong
Chief Med & Dev Officer
—
—
—
44,576
$445.76K
—
Beltran Pedro
President and CEO
—
—
—
44,576
$445.76K
—
McKenna Mark C.
Former Director
—
—
—
30,000
$300.00K
—
Schmid John P.
Former Director
—
—
—
30,000
$300.00K
—
Holman Albert A III
Former Director
—
—
—
30,000
$300.00K
—
Mehra Uneek
Former Officer
—
—
—
22,806
$228.06K
—
Elmelech Idan
COO & Principal Financial Ofcr
—
—
—
14,495
$144.95K
−2.3%
Cobo Marc
Principal Accounting Officer
—
—
—
14,141
$141.41K
+160.4%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Individual transactions

3
Insider
Date
Role
Action
Shares
Price
Amount
Chen Bihua
13 Feb 2024
CEO and Chairperson
Buy indirect
903,600
$10.00
$9.04M
Chen Bihua
13 Feb 2024
CEO and Chairperson
Buy indirect
1,427,040
$10.00
$14.27M
Chen Bihua
13 Feb 2024
CEO and Chairperson
Buy indirect
69,360
$10.00
$693.60K
Show all 3 transactions →

What was left out

Form 4 filings counted 43
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 26,355,657
History held since 13 Feb 2024